REVITOPE ONCOLOGY
Revitope is developing a novel approach to cancer immunotherapy. Cancer patients typically have strong cytotoxic immunity against viral pathogens while lacking immunity against their tumors. Revitope’s technology redirects an exisiting viral immune response to treat cancer. Revitope’s antibody peptide epitope complex (APEC) technology selectively delivers an immunodominant viral peptide to the tumor cell, thereby activating exisiting T cells that recognize the tumor as virally infected, and kill it.
REVITOPE ONCOLOGY
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2014-01-01
Address:
San Francisco, California, United States
Country:
United States
Website Url:
http://www.revitope.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
8.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins
Similar Organizations
Calimmune
Calimmune is a clinical-stage gene therapy company.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.revitope.com
- Host name: 152.121.199.104.bc.googleusercontent.com
- IP address: 104.199.121.152
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Revitope Oncology"
Revitope Oncology Inc. - Powered for Precision
Revitope Oncology, Inc. is a privately owned company in Cambridge, MA, that focuses on the development of next-generation T cell engager immunotherapies for a variety of solid cancer …See details»
Revitope Oncology - Crunchbase Company Profile
Revitope’s antibody peptide epitope complex (APEC) technology selectively delivers an immunodominant viral peptide to the tumor cell, thereby activating exisiting T cells that recognize the tumor as virally infected, and kill it.See details»
Revitope - LinkedIn
Revitope is an early stage biotechnology company focused on developing the next-generation of T cell redirecting biologics. Immune-based therapies are redefining how cancer is treated as clinical...See details»
Revitope—third-generation T cell engager immunotherapies
Revitope Oncology Announces Strategic Collaboration …
Jan 5, 2021 · Revitope's proprietary Precision Guided Antibody Tumor Engager â„¢ (Precision GATE) technology platform exploits co-expressed tumor antigens to enable the development of highly specific cancer...See details»
Revitope Oncology - Org Chart, Teams, Culture & Jobs | The Org
View Revitope Oncology's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Revitope And Junshi Biosciences Enter Into Research Collaboration …
Jul 14, 2020 · Revitope will leverage its proprietary protein engineering platform together with Junshi's novel antibody components to develop first-in-class dual-antigen targeting cancer …See details»
RevitopeOncology,Inc. - Nature
Revitope Oncology, Inc. is a privately owned company in Cambridge, MA, that focuses on the development of next-generation T cell engager immunotherapies for a variety of solid cancer …See details»
Revitope Oncology Appoints Biotech Industry ... - Associated Press …
Revitope Oncology, Inc. is a privately funded cancer therapeutics company with a focus on innovative tumor-specific antibody based biotherapeutics.See details»
Revitope will be open to CRO and CMO pitches within couple of …
Jan 15, 2021 · Revitope Oncology will be open to CRO and CMO pitches in a couple of months for a Phase I trial after it selects its development candidate, said Chief Scientific Officer …See details»
Revitope Oncology - VentureRadar
Website: http://revitope.com. Revitope is developing a novel class of T cell engaging antibody circuits that redirect T cells to tumors with broad therapeutic applications in immuno-oncology. …See details»
Revitope Enters into a License Agreement for Next-generation T …
BOSTON, Oct. 29, 2024 /PRNewswire/ -- Revitope Oncology Inc. (Revitope), a biotechnology company advancing a new class of precision cancer immunotherapies, announced today that …See details»
T-cell-engaging antibodies for the treatment of solid tumors
Early clinical evidence for the importance of T cells in cancer therapy was obtained with the approval in 1992 of recombinant IL-2 [1], a T-cell-activating cytokine, and the clinical impact …See details»
REV-400 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 · REV-400, Initially developed by Revitope Ltd., Now, its global highest R&D status is Discovery, Therapeutic Areas: Neoplasms, Active Indication: Solid tumor, Active Org.: …See details»
Revitope Oncology, Inc. Raises $8.5 Million to Continue …
Feb 8, 2016 · Revitope Oncology, Inc. is a privately-held cancer immunotherapy company developing a novel platform based on redirecting viral immunity for the purpose of developing …See details»
Revitope Oncology Adds Carsten Reinhardt, a Pioneer of Modern ...
CAMBRIDGE, Mass., Sept. 16, 2020 /PRNewswire/ -- Revitope Oncology, Inc., a biotechnology company advancing a new class of precision cancer immunotherapies today announced the …See details»
REV-500 - Drug Targets, Indications, Patents - Synapse
REV-500, Initially developed by Revitope Oncology, Inc., Now, its global highest R&D status is Discovery, Therapeutic Areas: Neoplasms, Active Indication: Solid tumor, Active Org.: …See details»
REV-200 - Drug Targets, Indications, Patents - Synapse - Patsnap
REV-200: a CD3 modulators Drug, Initially developed by Revitope Ltd., Now, its global highest R&D status is Discovery, Mechanism: CD3 modulators(T cell surface glycoprotein CD3 …See details»
REV 400 - AdisInsight - Springer
Apr 8, 2021 · Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. REV 400 is a T-cell engaging bi-specific antibody against …See details»
REV-300 - Drug Targets, Indications, Patents - Synapse
REV-300: a CD3 modulators Drug, Initially developed by Revitope Ltd., Now, its global highest R&D status is Discovery, Mechanism: CD3 modulators(T cell surface glycoprotein CD3 …See details»